Developmental Milestone Payments Clause Samples
Developmental Milestone Payments. As partial consideration for the grant to OPIANT of the rights under Section 3.1 the Parties agree to the following:
Developmental Milestone Payments. As provided for in Paragraph 6.4 of this Agreement and subject to the Most Favored Licensee definition of Paragraph 2.11, Licensee agrees to pay PHS a nonrefundable developmental milestone payments associated with specific Licensed Fields of Use as set forth below:
(a) For the development of Therapeutics (Appendix B(I)(a))
(1) A Validation Milestone Payment, as additional consideration indicative of the value of the Licensed Patent Rights, in the amount of [**] Dollars ($[**]). The Validation Milestone Payment is due upon each occurrence of the [**], and where [**] (a) is for a Licensed Product or (b) for a product produced by a Licensed Process, or (c) contains descriptions of materials or methods within the scope of the Licensed Patent Rights. Notwithstanding the foregoing, the total amount of any benchmark payments under this Paragraph (a)(1) shall not exceed [**] Dollars ($[**]). Each payment is due upon achieving the milestone and is payable within [**] days thereof. The obligation to pay the Validation Milestone Payment survives any termination or expiration of this Agreement.
(2) A Clinical Milestone Payment upon achieving the first [**] in the amount of [**] Dollars ($[**]). The Clinical Milestone Payment is due upon achieving the milestone and is payable to PHS within [**] days thereof. The obligation to pay the Clinical Milestone Payment survives any termination or expiration of this Agreement
(3) A Regulatory Approval Milestone Payment, upon achieving the first occurrence of, [**], for example [**], for a Licensed Product, a Licensed Process, or a product made by a Licensed Process or from a Licensed Product, from the [**], in the amount of [**] Dollars ($[**]). The Regulatory Approval Milestone Payment is due upon achieving the milestone and is payable to PHS within [**] days thereof. The obligation to pay the Regulatory Milestone Payment survives any termination or expiration of this Agreement.
(b) For the development of Diagnostics (Appendix B(I)(b))
(1) A Regulatory Milestone Payment, in the amount of [**] Dollars ($[**]), upon the first occurrence of the [**], where such [**] is for a diagnostic and/or prognostic product that [**]. For purposes of this Paragraph activity includes but is not limited to [**]. This milestone payment is due upon achieving the milestone and is payable to PHS within [**] days thereof. The obligation to pay the Regulatory Milestone Payment survives any termination or expiration of this Agreement. Upon the Effectiv...
Developmental Milestone Payments. On a Product-by-Product basis, AstraZeneca will make one-time milestone payments to Pieris (each, a “Developmental Milestone Payment”) upon the first achievement of the development and regulatory milestone events set forth in this Section 9.3 (each, a “Developmental Milestone Event”) with respect to the Lead Product, each CoDev Product, and each AZ Dev Product, as applicable. Such Developmental Milestone Payments shall be made within [***] days of achievement of the corresponding Developmental Milestone Event.
Developmental Milestone Payments. SKK shall pay to Crinetics the one-time, non-refundable and non-creditable payments set forth in the table below within thirty (30) days after the first achievement of each applicable Developmental milestone event in the Territory, as determined in accordance with Section 8.4 below, as applicable, and receipt of an invoice from Crinetics. For the avoidance of doubt, each Development milestone payment shall be payable only once for each Indication.
(a) For the First Indication Milestone I [***] [***] Milestone II [***] [***] Milestone III [***] [***] [***].
(b) For the Second Indication Milestone I [***] [***] Milestone II [***] [***] [***].
Developmental Milestone Payments. Milestone Event Milestone Payment Total U.S.$ 42,000,000
Developmental Milestone Payments. As partial consideration for the grant to OPIANT of the rights under Section 3.1 the Parties agree to the following:
4.2.1 Products. As partial consideration for the grant to OPIANT of the rights under Section 3.1 the Parties agree to the following milestones for the first Product containing ****: Successful Completion of the first pilot PK study in humans $ **** Upon the Successful Completion of the first PK study in humans; provided, that if OPIANT has not initiated a first PK study in humans by ****, then such milestone shall be due on **** $ **** Approval of the first NDA or its equivalent $ **** At the time when any milestone payment listed in the table above is due, if OPIANT has not paid all other milestone payments (if any) previously listed in such table, then at such time OPIANT shall pay all such unpaid previous milestone payments.
Developmental Milestone Payments. (For Licensed Products other than NMRA 266). With respect to Licensed Products other than NMRA 266, the following milestone payments shall apply to the occurrence of each respective milestone event detailed in the table below: #1 [***] [***] #2 [***] [***] #3 [***] [***] #4 [***] [***]
Developmental Milestone Payments